|
1
|
Carbonare L Dalle, Innamorati G and
Valenti MT: Transcription factor Runx2 and its application to bone
tissue engineering. Stem Cell Rev. 8:891–897. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen MM Jr: Perspectives on RUNX genes:
An update. Am J Med Genet A 149A. 2629–2646. 2009. View Article : Google Scholar
|
|
3
|
Otto F, Thornell AP, Crompton T, Denzel A,
Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen
BR, et al: Cbfa1, a candidate gene for cleidocranial dysplasia
syndrome, is essential for osteoblast differentiation and bone
development. Cell. 89:765–771. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Otto F, Lübbert M and Stock M: Upstream
and downstream targets of RUNX proteins. J Cell Biochem. 89:9–18.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valenti MT, Garbin U, Pasini A, Zanatta M,
Stranieri C, Manfro S, Zucal C and Carbonare L Dalle: Role of
ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs)
and Runx2 and PPARγ2 expression in MSCs-like of osteoporotic
patients. PloS One. 6:e203632011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jensen ED, Schroeder TM, Bailey J,
Gopalakrishnan R and Westendorf JJ: Histone deacetylase 7
associates with Runx2 and represses its activity during osteoblast
maturation in a deacetylation-independent manner. J Bone Miner Res.
23:361–372. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yousfi M, Lasmoles F and Marie PJ: TWIST
inactivation reduces CBFA1/RUNX2 expression and DNA binding to the
osteocalcin promoter in osteoblasts. Biochem Biophys Res Commun.
297:641–644. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu R, Liu W, Li H, Yang L, Chen C, Xia ZY,
Guo LJ, Xie H, Zhou HD, Wu XP and Luo XH: A Runx2/miR-3960/miR-2861
regulatory feedback loop during mouse osteoblast differentiation. J
Biol Chem. 286:12328–12339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ge C, Xiao G, Jiang D, Yang Q, Hatch NE,
Roca H and Franceschi RT: Identification and functional
characterization of ERK/MAPK phosphorylation sites in the Runx2
transcription factor. J Biol Chem. 284:32533–32543. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lau CC, Harris CP, Lu XY, Perlaky L,
Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos
AG, et al: Frequent amplification and rearrangement of chromosomal
bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes
Cancer. 39:11–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kayed H, Jiang X, Keleg S, Jesnowski R,
Giese T, Berger MR, Esposito I, Löhr M, Friess H and Kleeff J:
Regulation and functional role of the Runt-related transcription
factor-2 in pancreatic cancer. Br J Cancer. 97:1106–1115. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Endo T, Ohta K and Kobayashi T: Expression
and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells.
J Clin Endocrinol Metab. 93:2409–2412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Owens TW, Rogers RL, Best SA, Ledger A,
Mooney AM, Ferguson A, Shore P, Swarbrick A, Ormandy CJ, Simpson
PT, et al: Runx2 is a novel regulator of mammary epithelial cell
fate in development and breast cancer. Cancer Res. 74:5277–5286.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY
and Kuo PL: Lung tumor-associated osteoblast-derived bone
morphogenetic protein-2 increased epithelial-to-mesenchymal
transition of cancer by Runx2/Snail signaling pathway. J Biol Chem.
286:37335–37346. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Niu DF, Kondo T, Nakazawa T, Oishi N,
Kawasaki T, Mochizuki K, Yamane T and Katoh R: Transcription factor
Runx2 is a regulator of epithelial-mesenchymal transition and
invasion in thyroid carcinomas. Lab Invest. 92:1181–1190. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li L and Li W: Epithelial-mesenchymal
transition in human cancer: Comprehensive reprogramming of
metabolism, epigenetics, and differentiation. Pharmacol Ther.
150:33–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carbonare L Dalle, Frigo A, Francia G,
Davì MV, Donatelli L, Stranieri C, Brazzarola P, Zatelli MC,
Menestrina F and Valenti MT: Runx2 mRNA expression in the tissue,
serum, and circulating non-hematopoietic cells of patients with
thyroid cancer. J Clin Endocrinol Metab. 97:E1249–E1256. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morgan RT, Woods LK, Moore GE, Quinn LA,
McGavran L and Gordon SG: Human cell line (COLO 357) of metastatic
pancreatic adenocarcinoma. Int J Cancer. 25:591–598. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim YW, Kern HF, Mullins TD, Koriwchak MJ
and Metzgar RS: Characterization of clones of a human pancreatic
adenocarcinoma cell line representing different stages of
differentiation. Pancreas. 4:353–362. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lieber M, Mazzetta J, Nelson-Rees W,
Kaplan M and Todaro G: Establishment of a continuous tumor-cell
line (panc-1) from a human carcinoma of the exocrine pancreas. Int
J Cancer. 15:741–747. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Parekh D, Ishizuka J, Townsend CM Jr,
Haber B, Beauchamp RD, Karp G, Kim SW, Rajaraman S, Greeley G Jr
and Thompson JC: Characterization of a human pancreatic carcinoid
in vitro: Morphology, amine and peptide storage, and secretion.
Pancreas. 9:83–90. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Soule HD, Vazguez J, Long A, Albert S and
Brennan M: A human cell line from a pleural effusion derived from a
breast carcinoma. J Natl Cancer Inst. 51:1409–1416. 1973.PubMed/NCBI
|
|
23
|
Keydar I, Chen L, Karby S, Weiss FR,
Delarea J, Radu M, Chaitcik S and Brenner HJ: Establishment and
characterization of a cell line of human breast carcinoma origin.
Eur J Cancer. 15:659–670. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stone KR, Mickey DD, Wunderli H, Mickey GH
and Paulson DF: Isolation of a human prostate carcinoma cell line
(DU 145). Int J Cancer. 21:274–281. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tai S, Sun Y, Squires JM, Zhang H, Oh WK,
Liang CZ and Huang J: PC3 is a cell line characteristic of
prostatic small cell carcinoma. Prostate. 71:1668–1679. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horoszewicz JS, Leong SS, Kawinski E, Karr
JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LNCaP model of
human prostatic carcinoma. Cancer Res. 43:1809–1818.
1983.PubMed/NCBI
|
|
27
|
Niforou KM, Anagnostopoulos AK, Vougas K,
Kittas C, Gorgoulis VG and Tsangaris GT: The proteome profile of
the human osteosarcoma U2OS cell line. Cancer Genomics Proteomics.
5:63–78. 2008.PubMed/NCBI
|
|
28
|
Billiau A, Edy VG, Heremans H, Van Damme
J, Desmyter J, Georgiades JA and De Somer P: Human interferon: Mass
production in a newly established cell line, MG-63. Antimicrob
Agents Chemother. 12:11–15. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carbonare L Dalle, Valenti MT, Bertoldo F,
Fracalossi A, Balducci E, Azzarello G, Vinante O and Lo Cascio V:
Amino-bisphosphonates decrease hTERT gene expression in breast
cancer in vitro. Aging Clin Exp Res. 19:91–96. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valenti MT, Carbonare L Dalle, Bertoldo F,
Donatelli L and Lo Cascio V: The effects on hTERT gene expression
is an additional mechanism of amino-bisphosphonates in prostatic
cancer cells. Eur J Pharmacol. 580:36–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gatta V, Drago D, Fincati K, Valenti MT,
Carbonare L Dalle, Sensi SL and Zatta P: Microarray analysis on
human neuroblastoma cells exposed to aluminum, β(1–42)-amyloid or
the beta (1–42)-amyloid aluminum complex. PloS One. 6:e159652011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murayama T, Kawasoe Y, Yamashita Y, Ueno
Y, Minami S, Yokouchi M and Komiya S: Efficacy of the
third-generation bisphosphonate risedronate alone and in
combination with anticancer drugs against osteosarcoma cell lines.
Anticancer Res. 28:2147–2154. 2008.PubMed/NCBI
|
|
33
|
Valenti MT, Zanatta M, Donatelli L,
Viviano G, Cavallini C, Scupoli MT and Carbonare L Dalle: Ascorbic
acid induces either differentiation or apoptosis in MG-63
osteosarcoma lineage. Anticancer Res. 34:1617–1627. 2014.PubMed/NCBI
|
|
34
|
Galindo M, Pratap J, Young DW,
Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS and van
Wijnen AJ: The bone-specific expression of Runx2 oscillates during
the cell cycle to support a G1-related antiproliferative function
in osteoblasts. J Biol Chem. 280:20274–20285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Valenti MT, Carbonare L Dalle, Donatelli
L, Bertoldo F, Giovanazzi B, Caliari F and Lo Cascio V: STEAP mRNA
detection in serum of patients with solid tumours. Cancer Lett.
273:122–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carbonare L Dalle, Gasparetto A, Donatelli
L, Dellantonio A and Valenti MT: Telomerase mRNA detection in serum
of patients with prostate cancer. Urol Oncol. 31:205–210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pratap J, Lian JB and Stein GS: Metastatic
bone disease: Role of transcription factors and future targets.
Bone. 48:30–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li XQ, Lu JT, Tan CC, Wang QS and Feng YM:
RUNX2 promotes breast cancer bone metastasis by increasing integrin
α5-mediated colonization. Cancer Lett. 380:78–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang C, Long F, Wan J, Hu Y and He H:
MicroRNA-205 acts as a tumor suppressor in osteosarcoma via
targeting RUNX2. Oncol Rep. 35:3275–3284. 2016.PubMed/NCBI
|
|
41
|
Ge C, Zhao G, Li Y, Li H, Zhao X, Pannone
G, Bufo P, Santoro A, Sanguedolce F, Tortorella S, et al: Role of
Runx2 phosphorylation in prostate cancer and association with
metastatic disease. Oncogene. 35:366–376. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Blyth K, Vaillant F, Jenkins A, McDonald
L, Pringle MA, Huser C, Stein T, Neil J and Cameron ER: Runx2 in
normal tissues and cancer cells: A developing story. Blood Cells
Mol Dis. 45:117–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He Y, de Castro LF, Shin MH, Dubois W,
Yang HH, Jiang S, Mishra PJ, Ren L, Gou H, Lal A, et al: p53 loss
increases the osteogenic differentiation of bone marrow stromal
cells. Stem Cells. 33:1304–1319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Engelmann D and Pützer BM: Emerging from
the shade of p53 mutants: N-terminally truncated variants of the
p53 family in EMT signaling and cancer progression. Sci Signal.
7:re92014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chimge NO, Baniwal SK, Little GH, Chen YB,
Kahn M, Tripathy D, Borok Z and Frenkel B: Regulation of breast
cancer metastasis by Runx2 and estrogen signaling: The role of
SNAI2. Breast Cancer Res. 13:R1272011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee JY and Kong G: Roles and epigenetic
regulation of epithelial-mesenchymal transition and its
transcription factors in cancer initiation and progression. Cell
Mol Life Sci. Jul 26–2016.(Epub ahead of print). View Article : Google Scholar
|
|
47
|
Akech J, Wixted JJ, Bedard K, van der Deen
M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR,
Altieri DC, et al: Runx2 association with progression of prostate
cancer in patients: Mechanisms mediating bone osteolysis and
osteoblastic metastatic lesions. Oncogene. 29:811–821. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Leong DT, Lim J, Goh X, Pratap J, Pereira
BP, Kwok HS, Nathan SS, Dobson JR, Lian JB, Ito Y, et al:
Cancer-related ectopic expression of the bone-related transcription
factor RUNX2 in non-osseous metastatic tumor cells is linked to
cell proliferation and motility. Breast Cancer Res. 12:R892010.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Baniwal SK, Khalid O, Gabet Y, Shah RR,
Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA and Frenkel B:
Runx2 transcriptome of prostate cancer cells: Insights into
invasiveness and bone metastasis. Mol Cancer. 9:2582010. View Article : Google Scholar : PubMed/NCBI
|
